{"id":71574,"date":"2025-11-03T18:56:13","date_gmt":"2025-11-03T18:56:13","guid":{"rendered":"https:\/\/www.europesays.com\/se\/71574\/"},"modified":"2025-11-03T18:56:13","modified_gmt":"2025-11-03T18:56:13","slug":"novo-nordisk-om-budkonflikten-lagen-pa-var-sida","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/71574\/","title":{"rendered":"Novo Nordisk om budkonflikten: Lagen p\u00e5 v\u00e5r sida"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Enligt vad <strong>Novo Nordisk<\/strong> har uppgett f\u00f6r Reuters har bolaget f\u00f6ljt &#8221;alla restriktioner i samband med <strong>Pfizers <\/strong>bud, och vi \u00e4r \u00f6vertygade om att fakta och lagen \u00e4r p\u00e5 v\u00e5r sida&#8221;, skriver Marketwire.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">&#8221;Pfizer har fundamentalt fel om konkurrensdynamiken p\u00e5 denna marknad&#8221;, uppgav Novo Nordisk i en skriftlig kommentar till Reuters och fortsatte &#8221;vi \u00e4r \u00f6vertygade om att denna transaktion inte ger upphov till n\u00e5gra konkurrensproblem&#8221;.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Tidigare p\u00e5 m\u00e5ndagen inl\u00e4mnade Pfizer en st\u00e4mning mot Metsera, f\u00f6retagets kontrollerande aktie\u00e4gare och Novo Nordisk till en distriktsdomstol i Delaware, USA. Enligt det amerikanska l\u00e4kemedelsbolaget skulle Novo Nordisk bud p\u00e5 Metsera &#8221;utg\u00f6ra en konkurrensbegr\u00e4nsande handling fr\u00e5n Novo Nordisks sida f\u00f6r att skydda sin dominerande marknadsposition inom GLP-1-produkter genom att f\u00f6rv\u00e4rva och eliminera en ny amerikansk konkurrent innan den f\u00e5r st\u00f6d fr\u00e5n Pfizer&#8221;.<\/p>\n","protected":false},"excerpt":{"rendered":"Enligt vad Novo Nordisk har uppgett f\u00f6r Reuters har bolaget f\u00f6ljt &#8221;alla restriktioner i samband med Pfizers bud,&hellip;\n","protected":false},"author":2,"featured_media":51342,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,6456,6457,6458,34,31,33,32,30],"class_list":{"0":"post-71574","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-novo-nordisk-adr","12":"tag-novo-nordisk-b","13":"tag-pfizer","14":"tag-se","15":"tag-svenska","16":"tag-sverige","17":"tag-sweden","18":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115487295608004345","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/71574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=71574"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/71574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/51342"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=71574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=71574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=71574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}